Screener
Jazz Pharmaceuticals JAZZ Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $100.0 | $122.1 |
| Accrued liabilities | 1,022.4 | 1,034.2 |
| Current portion of long-term debt | 1,030.5 | 1,029.9 |
| Income taxes payable | 93.7 | 56.3 |
| Total current liabilities | 2,246.6 | 2,242.5 |
| Long-term debt, less current portion | 4,324.2 | 4,328.4 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's accrued expenses?
- Jazz Pharmaceuticals (JAZZ) reported accrued expenses of $1.02B in Q1 2026.
- How has Jazz Pharmaceuticals's accrued expenses changed year-over-year?
- Jazz Pharmaceuticals's accrued expenses decreased by 3.9% year-over-year, from $1.06B to $1.02B.
- What is the long-term trend for Jazz Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's accrued expenses has grown at a 24.0% compound annual growth rate (CAGR), from $352.73M to $1.03B.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Jazz Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude